Skye Bioscience, Inc. 8-K

What Happened

• On May 26, 2026 Skye Bioscience, Inc. held its 2026 Annual Meeting; on May 28, 2026 the company filed a Certificate of Amendment with the Nevada Secretary of State to increase authorized common stock from 100,000,000 to 300,000,000 shares. The amendment does not change the company’s issued and outstanding shares.
• At the meeting (record date April 2, 2026), 35,126,884 shares were entitled to vote and 23,529,424 shares (66.98%) were present or represented by proxy (quorum). All six director nominees were elected, the selection of CBIZ CPAs P.C. as independent auditor for 2026 was ratified, the charter amendment was approved by stockholders, and the company’s executive compensation was approved on an advisory basis.

Key Details

• Authorized common shares increased from 100,000,000 to 300,000,000; Certificate of Amendment filed May 28, 2026.
• Charter Amendment vote: For 20,594,286; Against 2,875,605; Abstain 59,533.
• Director election results (For / Withhold; large broker non-votes 9,823,126): Paul Grayson 13,194,721 / 511,577; Deborah Charych 13,293,551 / 412,747; Punit Dhillon 13,466,198 / 240,100; Annalisa Jenkins 13,491,428 / 214,870; Karen Smith 13,036,640 / 669,658; Andrew J. Schwab 13,408,440 / 297,858.
• Auditor ratification: CBIZ CPAs P.C. — For 22,802,045; Against 542,634; Abstain 184,745. Say-on-pay (advisory): For 12,696,055; Against 909,925; Abstain 100,318 (plus broker non-votes 9,823,126).

Why It Matters

• Increasing authorized shares gives the company flexibility to issue additional stock in the future for capital raises, equity compensation, or acquisitions. That flexibility can be useful for funding growth but may lead to dilution if new shares are issued.
• The amendment itself did not issue new shares or change current ownership; investors should monitor future filings (e.g., equity issuance, shelf registrations) for any actions that would dilute existing shareholders.
• The re-election of the board and ratification of the auditor provide continuity in governance and financial oversight following the vote.